Pharmacist Moms Group^™

A compliance expert outlines what's next for GLP-1 compounding oversight and how pharmacists can stay audit-ready.

Welcome back to another Pharmacy Times Practice Pearls series. In this episode titled, 'Transitions of Care in Multiple Myeloma: Why Handoffs Remain the Biggest Operational Challenge,' Zahra Mahmoudjafari led the conversation about the following question: 1. Transitions of care has emerged as the single most consistent operational challenge, outranking efficacy and safety concerns. Why is this difficult, and where are the pain points?

Timothy Clifford, PharmD, outlines how quality-of-life impact, comorbid conditions, and prior therapy failures guide biologic selection for CRSwNP.

Aderonke Adeboye, PharmD, discusses the clinical red flags that signal a patient with CSU needs advanced therapy and how specialty pharmacists guide treatment selection and support long-term adherence for biologics and emerging oral agents.

Learn how new nonhormonal menopause drugs ease hot flashes, improve sleep, and who benefits—plus key side effects and liver monitoring.

Phase 3 SKYLIGHT and OASIS trials show rapid relief of menopausal hot flashes—often within one week—plus strong safety data, with sleep outcomes under close study.

GoodRx's David Graziano breaks down how fluctuating acquisition costs, narrow formularies, and retrospective reimbursement adjustments are squeezing independent pharmacies—and what solutions exist to help them remain competitive.

Monica Dougherty, PharmD, BCACP, explains how the 2026 GOLD guideline updates use blood eosinophil counts to guide biologic therapy decisions for patients with COPD.

Pharmacy Times speaks with Caitlin Jones, PHD, on how evidence gaps, opioid dependence, and misaligned incentives can undermine pain care.